Atlas Trials

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Clinical trial NCT03376763 · COMPLETED

Trial details

NCT number
NCT03376763
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
SchizophreniaAntipsychoticsLong-Acting InjectionLAIAripiprazole
Start date
2017-11-21
Primary completion
2021-11-19
Enrollment
201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.